$1.110
-0.010 (-0.89%)Zum Schluss
Umsatzquellen von NAII
Natural Alternatives International Inc (NAII) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Private Label Contract Manufacturing, accounting for 95.3% of total sales, equivalent to $33.81M. Another important revenue stream is Patent & trademark licensing. Understanding this composition is critical for investors evaluating how NAII navigates market cycles within the Pharmaceuticals industry.
Profitabilität und Margen von NAII
Evaluating the bottom line, Natural Alternatives International Inc maintains a gross margin of 5.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7.89%, while the net margin is -39.24%. These profitability ratios, combined with a Return on Equity (ROE) of -34.96%, provide a clear picture of how effectively NAII converts its operational activities into shareholder value.
NAII im Vergleich zur Peergroup
In the context of the broader market, NAII competes directly with industry leaders such as ENVB and BNKK. With a market capitalization of $6.95M, it holds a significant position in the sector. When comparing efficiency, NAII's gross margin of 5.00% stands against ENVB's N/A and BNKK's 33.61%. Such benchmarking helps identify whether Natural Alternatives International Inc is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Natural Alternatives International Inc
The company's revenue has shown some growth, with Q3 2026 net sales increasing by 23% year-over-year to $35.5 million. However, net income remains negative, with a loss of $4.3 million reported for Q3 2026 and a gross margin that fluctuated significantly, peaking at 11.65% in Q1 2026 but dropping to 5.00% in Q4 2026.
Financials
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.